Protalix appoints new COO
This article was originally published in Scrip
Executive Summary
Protalix BioTherapeutics (Israel) has appointed Tzvi Palash to the newly created position of chief operating officer. He will be responsible for overseeing manufacturing activities and implementing the expansion phase of the firm's facility as it moves from being an R&D organisation to a fully integrated biotech company. Mr Palash has more than 25 years' experience in commercial operations in the healthcare industry, having previously served as general manager at ColBar LifeScience (a subsidiary of Johnson & Johnson), plant manager at CTS, QA manager at Teva Pharmaceutical Industries and production manager at Interpharm Laboratories (a subsidiary of Serono).